BridgeBio Oncology Therapeutics (BBOT) Other financing activities (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Other financing activities for 3 years, with the latest figure at $416000.0 in Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $416000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $373.9 million (up 7521.06% YoY) and the FY2025 annual result came in at $373.5 million, up 718086.54% from the prior year.
• Other financing activities fell to $416000.0 in Q1 2026 per BBOT's latest filing, from $373.5 million in the prior quarter.
• Over five years, Other financing activities peaked at $373.5 million in Q4 2025 and troughed at -$5.1 million in Q3 2025.
• A 3-year average of $53.4 million and a median of $416000.0 in 2026 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 37075.94% in 2025, down 26.37% in 2025.
• Over 3 years, Other financing activities stood at -$1.0 million in 2024, then jumped by 37075.94% to $373.5 million in 2025, then plunged by 99.89% to $416000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $416000.0, $373.5 million, and -$5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.